Fundraising FoxMarcelo Bigal
Former Venture Partner at Versant Ventures
Pennsylvania
Writes $100K – $5M checks · typically $1.5M
Find your path to Marcelo
Sign up to see every warm intro you have to Marcelo
- Paths you didn't know you had: your email and LinkedIn already hold routes to Marcelo. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Marcelo Bigal is President and CEO of Ventus Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines in immunology, inflammation, and neurology using structural biology and computational chemistry approaches. He brings over 16 years of pharmaceutical experience spanning R&D, medical, and scientific affairs, including previous roles as Head of R&D, Chief Scientific Officer, and Chief Medical Officer at Teva, and Chief Medical Officer at Labrys, where he led development of fremanezumab, a CGRP monoclonal antibody approved in the US, Canada, and EU. Bigal previously held faculty and research director positions at Albert Einstein College of Medicine and multiple headache research centers, and has authored approximately 330 peer-reviewed publications and edited six neurology textbooks.
Frequently asked questions
- Who is Marcelo Bigal?
- Marcelo Bigal is President and CEO of Ventus Therapeutics, a clinical-stage biopharmaceutical company developing novel medicines in immunology, inflammation, and neurology using structural biology and computational chemistry approaches. He brings over 16 years of pharmaceutical experience spanning R&D, medical, and scientific affairs, including previous roles as Head of R&D, Chief Scientific Officer, and Chief Medical Officer at Teva, and Chief Medical Officer at Labrys, where he led development of fremanezumab, a CGRP monoclonal antibody approved in the US, Canada, and EU. Bigal previously held faculty and research director positions at Albert Einstein College of Medicine and multiple headache research centers, and has authored approximately 330 peer-reviewed publications and edited six neurology textbooks.
- What check size does Marcelo Bigal write?
- Marcelo Bigal typically writes checks of $100K – $5M.
Founder mafias
USP - Universidade de São Paulo mafia79
Also came through, then founded or led a company.
Versant Ventures mafia17
Also came through, then founded or led a company.
Santa Ana Bio mafia2
Also came through, then founded or led a company.
About this profile. Compiled from public sources — Versant Ventures's own website and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights